Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis (Q28736049)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: 8 February 2017)

Language	Label	Description	Also known as
English	Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis	scientific article (publication date: 8 February 2017)

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

systematic review

1 reference

PubMed publication ID

1 reference

PubMed publication ID

0 references

Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

selective serotonin reuptake inhibitor

1 reference

PubMed publication ID

quality of life

1 reference

23 July 2019

depressive disorder

1 reference

23 July 2019

second-generation antidepressive agents

1 reference

2 October 2019

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis

1 reference

10.1186/S12888-017-1311-5

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1186/S12888-017-1311-5

Christian Gluud

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Janus C Jakobsen

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Katja Leth-Møller

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

author name string

Kiran Kumar Katakam

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Anne Schou

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Signe Gade Hellmuth

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Sandra Elkjær Stallknecht

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Maria Iversen

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Marianne Bjørnø Banke

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Iggiannguaq Juhl Petersen

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Sarah Louise Klingenberg

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Jesper Krogh

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Sebastian Elgaard Ebert

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Jane Lindschou

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

language of work or name

0 references

publication date

8 February 2017

4 references

13 March 2019

23 July 2019

2 October 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

5 references

13 March 2019

23 July 2019

2 October 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

58

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

copyright license

Creative Commons Attribution 4.0 International

3 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

23 July 2019

Europe PubMed Central

2 October 2019

copyright status

0 references

on focus list of Wikimedia project

0 references

Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Convincing Evidence from Controlled and Uncontrolled Studies on the Lipid-Lowering Effect of a Statin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Industry sponsorship and research outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Exercise for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Placebo interventions for all clinical conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Antidepressant drug effects and depression severity: a patient-level meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Antidepressants versus placebo for depression in primary care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Active placebos versus antidepressants for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

A rating scale for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

An Inventory for Measuring Depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

17 March 2017

The Effect of Gepirone‐ER in the Treatment of Sexual Dysfunction in Depressed Men

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

7 April 2017

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

7 April 2017

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

7 April 2017

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

7 April 2017

Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

DEPERROR: Risks of systematic errors in drug and non-drug randomized clinical trials assessing intervention effects in patients with unipolar depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Consumption of antidepressants in Italy: recent trends and their significance for public health

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

SPIRIT 2013 statement: defining standard protocol items for clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Exercise fails to improve neurocognition in depressed middle-aged and older adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Exercise and pharmacotherapy in the treatment of major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Relaxing the rule of ten events per variable in logistic and Cox regression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Clinical trials and the response rate illusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

The cost of dichotomising continuous variables

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Cognitive therapy vs medications in the treatment of moderate to severe depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

The functional neuroanatomy of the placebo effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Antidepressant versus placebo for depressed elderly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Empirical assessment of effect of publication bias on meta-analyses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

The QLDS: a scale for the measurement of quality of life in depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Use of a standardized documentation system (BLIPS/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine, and placebo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Paroxetine in the treatment of depression: a comparison with imipramine and placebo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A placebo- and imipramine-controlled study of paroxetine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind comparison of paroxetine, imipramine, and placebo in major depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A double-blind, placebo-controlled study of paroxetine in depressed outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

3 June 2018

GPs in England prescribed 2.7 million extra antidepressants during 2012 recession

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Effects of sertraline on sleep architecture in patients with depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Escitalopram in the acute treatment of depressed patients aged 60 years or older

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Sertraline treatment of co-occurring alcohol dependence and major depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Clinical efficacy of paroxetine in resistant depression.

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Fluoxetine treatment of cocaine-dependent patients with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

What does the HAMD mean?

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

A Placebo-Controlled Study of Fluoxetine Versus Imipramine in the Acute Treatment of Atypical Depression

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

The Oral Dose-Effect Relationship for Fluvoxamine: a Fixed-Dose Comparison Against Placebo in Depressed Outpatients

1 reference

https://api.crossref.org/works/10.1186%2FS12888-016-1173-2

21 January 2018

Dichotomizing continuous variables in statistical analysis: a practice to avoid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Clinical features and efficacy of escitalopram treatment for geriatric depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Escitalopram in the treatment of depressed elderly patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Accelerating symptom-reduction in late-life depression: a double-blind, randomized, placebo-controlled trial of sleep deprivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Efficacy of controlled-release paroxetine in the treatment of late-life depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5299662

27 November 2018

Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled study of sertraline in depressed recently abstinent alcoholics

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of paroxetine compared with placebo in outpatients with major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of fluoxetine on noradrenergic mediated growth hormone release: A double blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled trial of paroxetine in the treatment of major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paroxetine in major depression: a double-blind trial with imipramine and placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The predictive value of the dexamethasone suppression test. A placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dexamethasone suppression test and response to placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A fixed-dose clinical trial of fluoxetine in outpatients with major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives]

1 reference

https://pubmed.ncbi.nlm.nih.gov/28178949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12888-016-1173-2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s12888-016-1173-2

release_nkcymb7qlnbopbwuvkimi4jxfm

1 reference

https://api.fatcat.wiki/v0/release/nkcymb7qlnbopbwuvkimi4jxfm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178949%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28736049&oldid=2177854873"